A multicenter Japanese study led by researchers at Tokyo University of Science has confirmed that the epithelial phospholipid, phosphatidylinositol bisphosphate, could partially halt cancer progression, making it an attractive new target molecule for novel anticancer treatments.
A target-agnostic search has yielded a patient-derived antibody that activated the innate immune system, researchers from Atreca and Stanford University reported in the May 4,2022, issue of the ProceedingsoftheNationalAcademyofSciences.
Age is the biggest risk factor for just about every common disease in high-income countries, which suggests that slowing down cellular aging would have massive effects on individual and public health. Delaying the average onset of Alzheimer’s disease by five years, for example, would roughly halve its prevalence. But in practice, there are no approved anti-aging medications.
“People often think about the genome as the blueprint of the organism, but that’s not really correct,” Steven Quake told reporters at a Science press briefing earlier this week. “The genome is more of a parts list, because every cell type uses different parts.” Quake is president of the Chan Zuckerberg Biohub Network, and professor of bioengineering and applied physics at Stanford University.
More than 10% of Americans suffer from chronic pain, and how to prevent acute pain from turning chronic has been a critical question in pain research. But according to a study published in the May 11, 2022, issue of Science Translational Medicine, that approach has it backwards. In several animal models of pain, the resolution of acute pain was an active process. Chronic pain happened when those active processes failed to occur.
Type 2 diabetes is known to involve many different underlying mechanisms, but the considerable heterogeneity in the phenotype is mostly ignored in how it is treated. Now, researchers at University of Dundee, U.K., have developed a method for visualizing this heterogeneity and shown how the risks of complications, such as chronic kidney disease or peripheral neuropathy, differ by phenotypes.
There are 40 years of history behind the development of phosphoinositide 3-kinase (PI3K) inhibitors, Rebecca Dent told her audience at ESMO Breast Cancer 2022. And there have been success stories. There are five FDA-approved PI3K inhibitors in several cancer types, and in April, the FDA approved Vijoice (alpelisib; Novartis AG) for PIK3CA-related overgrowth spectrum, a rare disorder resulting from germline mutations of PIK3CA.